Health ❯Healthcare

Pharmaceuticals

Mergers and Acquisitions Company Performance Vaccine Regulation Market Competition Machine Learning Precision Medicine Respiratory Viruses Acquisitions Market Risks Genetic Engineering

FDA Approves Yeztugo, Twice-Yearly HIV Prevention Injection

High pricing paired with uncertain backing by major HIV funders threatens access in low-income nations

FDA Approves Regeneron and Sanofi’s Dupixent for Bullous Pemphigoid

Albumin-PLGA Nanoparticles Enable Ultrahigh Drug Loading and Six-Month Stability

Stories older than 24h

FDA Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

FDA Launches National Priority Voucher Program to Slash Drug Review Times

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins

Long-Term Desogestrel Use Linked to Slight Rise in Brain Tumor Risk

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

Robinhood Excluded From June S&P 500 Rebalance Despite Doubling in Value

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial

GPT-4 Identifies Existing Drug Combinations That Kill Breast Cancer Cells

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women